@article{article, title  = {{Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with intermediate-risk non–muscle-invasive bladder cancer (IR-NMIBC) with <i>FGFR3/2</i> alterations (alt) in THOR-2: Cohort 3 interim analysis.}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{http://dx.doi.org/10.1200/jco.2023.41.6_suppl.504 }},

 year = {{2023}},

 month = {{2}},

 author = {{Daneshmand S and Zaucha R and Gartrell BA and Lotan Y and Hussain SA and Lee EK and Procopio G and Galanternik F and Naini V and Carcione J and Triantos S et al}},

 doi = {{10.1200/jco.2023.41.6_suppl.504}},

 volume = {{41}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{6_suppl}},

 pages = {{504-504}},

 note = {{Accessed on 2024/12/22}}}